Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine


Pamela New, M.D.


Pamela New, M.D.

Pamela New, M.D.

Assistant Member
The Methodist Hospital Research Institute
Neuro-oncologist, Methodist Neurological Institute
Associate Professor of Neurosurgery
Baylor College of Medicine

Phone: 713-441-3800
Fax: 713-790-2609
E-mail: pnew@houstonmethodist.org


B.S. Northwestern University, Chicago, IL
M.D. Northwestern University, Chicago, IL

Postdoctoral Training

Residency, Cornell Medical Center, Houston, Texas
Residency, Baylor College of Medicine, Houston, Texas



Dr. Pamela New is a neuro-oncologist who began working in The Methodist Hospital system in October of 2003. Previously she worked at the University of Texas Health Science Center in San Antonio for 16 years. There she was part of the NABTT consortium (New Approaches To Brain Tumor Therapy), an NCI funded consortium of institutions which included Massachusetts General Hospital, Johns Hopkins University, Henry Ford Hospital, University of Pennsylvania, Emory University, Moffitt Cancer Center, University of Alabama, Wake Forest University and the Cleveland Clinic. At UT she worked with research patients and clinical patients.

Dr. New graduated with a B.S. and M.D. from Northwestern University. She completed her residency from the Cornell Medical Center and Baylor College of Medicine. Her clinical focus is on the treatment of primary brain tumors with special interest in high-grade gliomas and the treatment of brain metastases.

Description of Research

Dr. New’s work examines leptomeningeal disease and the treatment of neurological complications resulting from all cancers and cancer treatments. Brain Cancer, Brain Tumors, Chemotherapy, Intrathecal Therapy, Meningioma, Neuro-Oncology, Pituitary Tumor, Spinal Cord Tumor.

Recent Publications

Brem S, Grossman S, Carson K, New P, Phuphanich S, Alavi J, Mikkelsen T, Fisher J. Phase 2 Trial of Copper Depletion and Penicillamine as Antiangiogenesis Therapy of Glioblastoma. Neuro-Oncology 2005; 7(3):246-253.

Rudek M, Hartke C, Zabelina Y, Zhao M, New P, Baker S. A Sensitive Method for Determination of COL-3, a Chemically Modified Tetracycline, in Human Plasma using High-Performance Liquid Chromatography and Ultraviolet Detection. J Pharm Biomed Ana. 2005; 37(4) 751-756.

New P. Cyclooxygenase in the Treatment of Glioma: Its Complex Rolse in Signal Transduction. Cancer Control. 2004; 11(3): 152-164.

Batchelor T, Carson K, O’Neill A, Grossman S, Alavi J, New P, Hochberg F, Priet R. Treatment of Primary CNS Lymphoma with Methotrexate and Deferred Radiotherapy: A Report of NABTT 96-07. J. Clin. Oncol. 2003; 21 (6): 1044-1049.

New,P. Radiation Injury to the Nervous System. Current Opinion in Neurology 2001; 14:725-734.

Liotti M, Ramig L, Vogel D, New P, Cook C, Ingham R, Ingham J, Fox P. Hypophonia in Parkinson’s Disease: Neural Correlates of Voice Treatment with LSVT revealed by PET. Neurology 2003; 60 (3): 432-440.

Jaeckle KA, Batchelor T, O’Day SJ, Phupanich S, New P, Lesser G, Cohn A, Gilbert M, Aiken R, Heros D, Rogers L, Wong E, Fulton D, Gutheil JC, Baidas S, Kennedy JM, Mason W, Moots P, Russell C, Swinnen LJ, Howell SB. An open label trial of sustained-release cytarabine (DepoCyte) for the intrathecal treatment of solid tumor neoplastic meningitis.” J Neurooncol. 2002 May;57(3):231-9.

Tatlidil R, New P, Liotti M, Mayberg H, Fox P. FDG-PET in diffuse lewy body disease: a case report. Clin Nucl Med 2000; 25(12):1004-6

Tandon N, New P, Herman T, Hevezi J, Kagan-Hallet K, West A. Fulminant radiation induced necrosis after stereotactic radiation therapy to the posterior fossa - a case report and review of the literature. J. Neurosurgery 2001; 95(3):507-12.

Tatlidil R, Xiong J, New P, West A, Fox P. Language mapping in pretreatment planning of patients with cerebral arteriovenous malformation: a PET study. Clin Nucl Med 2000; 25(8):591-5.